In an era where technological advancements are revolutionizing drug development, Aptar Pharma and Nanopharm, an Aptar Pharma company, are proud to sponsor a cutting-edge webinar entitled, “In Silico Modelling for Orally Inhaled Drug Development: Clinical Insight From In Vitro Data Using Physiologically Based Pharmacokinetic Modelling.”
This webinar is specifically tailored for professionals at the forefront of drug development, including Heads of Drug Development, Formulation Development, Device Development, Research and Development, as well as Formulation Scientists, Principal Scientists, Senior Scientists, and C-level executives.
The webinar’s fourfold learning objectives are designed to enhance the attendees’ understanding and application of Physiologically Based Pharmacokinetic (PBPK) modelling in drug development. These objectives include:
- Identifying Drug Development Questions: Understanding how PBPK modelling can address specific challenges in drug development.
- Designing In Vitro Studies: Crafting studies that provide valuable input for PBPK models.
- Analyzing PBPK Simulation Results: Utilizing simulation results to guide critical drug development decision-making.
- Applying Insights to Drug Development: Integrating these methodologies to address unique challenges in attendees’ drug development processes.
The heart of the webinar lies in its focus on the recent advances in in vitro testing for orally inhaled and nasal drug products (OINDPs). These advancements have opened new avenues to consider the patient earlier in the drug development process. However, they capture only a fraction of the patient and disease variability. This is where physiologically based simulations become crucial. They integrate real patient data – such as airway surface areas, mucociliary clearance rates, and device usage – to simulate drug exposure both locally and systemically.
Attendees will gain insights into how PBPK modelling can predict clinical study outcomes and explore theoretical scenarios. Questions such as the influence of nasal product targeting on systemic exposure, the maximum dose for poorly soluble drugs, and the impact of device changes on drug delivery will be addressed.
More than just an introduction to PBPK models, this webinar is a deep dive into how these models work in tandem with in vitro and pre-clinical data, guiding the design of studies that benefit from in silico methods. The future of complex drug product development lies in the harmonious integration of in vitro and in silico approaches, necessitating a mutual understanding between these methodologies.
This webinar is an ideal opportunity for drug product developers seeking to expand their testing scope or anyone curious about the application of PBPK models in OINDPs.
Registration is now open, and attendance is free. To reserve your spot, please click on the links below.
Register for 9am London Session
Register for 3:30pm London Session
About Aptar Pharma
Aptar Pharma is part of AptarGroup, Inc., a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions and services. Aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has approximately 13,500 dedicated employees in 20 countries.
For more information, visit www.aptar.com/pharmaceutical
